Multi-Center Phase Ib Study of Intermittent Dosing of the MEK inhibitor, Selumetinib, in Patients with advanced Uveal Melanoma Not Previously Treated with a MEK Inhibitor
A study for patients with Uveal Melanoma using the study drug Selumetinib
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAQ6999
U.S. Govt. ID: NCT02768766
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out what effects, good and/or bad, intermittent dosing of the medication Selumetinib will have on you and your uveal melanoma. Selumetinib is a medication that blocks (or turns off) MEK, a protein activated in some uveal melanoma cells. Selumetinib is a MEK inhibitor. Blocking MEK may stop your cancer from growing.
This study is closed
Investigator
Mariam El-Ashmawy, MD, PhD
Do You Qualify?
Have you been diagnosed with metastatic uveal melanoma? Yes No
Are you able to swallow pills? Yes No
Do you have any history of heart disease? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE